SRC and breast carcinoma: Results of the present study have demonstrated that dasatinib effectively inhibited phosphorylation of c-Src in all cell lines tested (Figures 1, 2 and 3), and preferentially inhibited the growth of breast cancer cells of the basal B subtype (Additional file 2).